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Several prognostic factors in oncology have been established over the 
years, such as performance status, tumor size, and disease stage. The 
identification of prognostic and predictive factors is becoming increas-
ingly important in medical research, particularly as scientific discover-
ies have led to better understanding of diseases and genetics, resulting 
in tailored therapy. Advances in drug discovery and better understand-
ing of the mechanism of action, may also identify factors that may 
be prognostic and/or predictive. Prognostic or predictive factors may 
include patient characteristics such as age, ethnicity, sex, or smoking 
status, disease characteristics such as disease stage or nodal status, and 
molecular markers such as HER2 amplification and K ras mutation.
It can be challenging to distinguish whether a factor is prog-
nostic or predictive, based on what is reported in the literature. This 
article is intended to help the reader assess whether a factor is prog-
nostic and/or predictive.
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In the context of randomized clinical trials (RCTs), a large number of baseline factors are collected, and these factors 
have the potential to be prognostic and/or predictive. Any 
baseline factor may be prognostic and/or predictive; some 
examples of such factors are age, sex, race, and disease stage. 
Only baseline values of factors are assessed to be prognostic 
and/or predictive in RCTs because these are not affected by 
the treatment administered.1,2
The baseline values for factors that do change over 
time, such as performance status and prostate antigen level, 
are within the scope of this article; however, the postbaseline 
time-dependent changes and impact on outcomes are outside 
the scope of this article. The prognostic and predictive fac-
tor concepts discussed in this article are focused on RCTs. 
However, these concepts can be applied similarly to observa-
tional research and beyond.
Why Do Clinicians Need to Know About 
Prognostic and Predictive Factors?
Prognostic and predictive factors enable clinicians 
to make informed decisions about when to initiate, stop, or 
change therapy for a patient (prognostic factors), or what spe-
cific therapy to choose for an individual patient (predictive 
factors). Whereas randomization is important in clinical trial 
design to ensure balance between treatment arms, incorpo-
ration of prognostic factors into the randomization process 
(such as through stratification or minimization) increases bal-
ance within those important prognostic factors that may influ-
ence outcomes.3 Predictive factors are important in tailoring 
treatment to the appropriate patients. Uses of prognostic and 
predictive factors are summarized in Table 1.
What are Prognostic and Predictive 
Factors, and How Are They Different?
In the simplest case, a prognostic factor is a variable 
that is assessed before starting any treatment; based on the 
value (i.e., level) of this factor, the clinician can expect that a 
patient may have a better or worse clinical outcome (such as 
survival or response), regardless of what treatment the patient 
receives.4 For example, it is well recognized in oncology that 
patients with good baseline performance status do better than 
patients with worse performance status, or women often do 
better than men, regardless of the therapy being given. In this 
case, the relationship between the level of a factor (e.g., good 
performance status) with a patient’s outcome (e.g., survival) 
does not depend on the specific treatment given.
A factor is predictive when the treatment effect (such as 
response rate [RR]), within the levels of the factor (e.g., men 
and women), varies depending on the treatment given.5 That 
is, the relationship between the patient’s level of a factor (e.g., 
women) with a patient’s outcome (e.g., RR) depends on the 
specific treatment given.
A factor may be either prognostic and/or predic-
tive for a particular endpoint (e.g., survival) and may not 
have any relationship at all with other endpoints such as 
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progression-free survival or RR. In addition, predictive fac-
tors are often only predictive for a particular therapy or class 
of therapies. Furthermore, a factor may be both prognostic 
and predictive at the same time. Identification of an important 
predictive factor can change the standard of care, such that in 
the future, this factor can then become a prognostic factor. 
That is, type(s) of patients who are likely to do poorly with a 
new treatment would receive other treatments; the remaining 
patient type(s) who show benefit from this new treatment may 
then also show a prognostic effect. The differences between 
prognostic and predictive factors are summarized in Table 2.
How to Determine Whether a Factor 
is Prognostic or Predictive?
Assessing whether a baseline factor is prognostic or 
predictive can be done either prospectively (i.e., hypothesis 
testing by prespecifying this analysis in the protocol and/or 
statistical analysis plan) or retrospectively (i.e., hypothesis 
generating using exploratory analyses). The validity of pre-
specified analyses is obtained predominantly when the results 
are reproduced and consistent across studies, with an underly-
ing biologic plausibility.1,2 Increased confidence in such analy-
sis is greatly improved in large studies that are well-designed 
and minimize error and biases through randomization, blind-
ing, adequate follow-up, and prespecified analyses.2
Analyses to assess whether a factor is prognostic and/
or predictive typically use regression methods. The type 
of regression method depends on the type of endpoint. For 
example, typically Cox regression will be used for time-to-
event endpoints such as overall survival or progression-free 
survival, logistic regression will be used for binary endpoints 
such as responder (Yes/No), and linear regression will be 
used for continuous endpoints such as change in tumor size. 
Flowchart 1 illustrates a common approach to inferential 
models used to assess whether a baseline factor is prognostic 
and/or predictive; inferential models are prespecified and use 
methods to control for multiple testing. Flowchart 2 illustrates 
a common approach to exploratory model building to assess 
prognostic and/or predictive baseline factors.
Hypothetical Examples Illustrating 
Different Scenarios
The following examples discuss hypothetical results to 
illustrate different combinations of prognostic and/or predic-
tive factors. In each example, Tx A is the control, and Tx B is 
the experimental treatment.
Example 1—Sex: Neither prognostic nor predictive
In this example both women and men have a 30% RR 
on Tx A and a 60% RR on Tx B (Fig. 1A). Hence, the size and 
magnitude of the treatment effect (i.e., improvement of 30% on 
Tx B) was the same in both sexes. In addition, the RR for both 
treatments was similar (in this case, the same) for both sexes.
In a regression model evaluating the prognostic effect 
of sex, the p value for the sex effect was 0.75, supporting that 
sex is not prognostic.
Example 2—Sex: Prognostic but not predictive
In a hypothetical clinical trial, women on Tx A had an 
RR of 30%, whereas those on Tx B had an RR of 60%, a dif-
ference of 30% (Fig. 1B). In contrast, men on Tx A had an RR 
TABLE 1.  Uses for Prognostic and Predictive Factors
Prognostic Factor Predictive Factor
Contributes to understanding of disease process, such as when to initiate, 
stop, or change treatment.
Helps a physician determines whether a certain treatment is a good option for a 
specific patient, based on the individual patient’s characteristics.
Is used in clinical trial inclusion/exclusion criteria to ensure homogeneity 
of the study population.
Can also be used in clinical trial inclusion/exclusion criteria to further assess the 
treatment effect, specifically in patients most likely to have increased benefit 
and/or decreased risk and to further quantify the benefit/risk.
Is used in clinical trial randomization process and/or statistical analyses 
to ensure balance between treatment arms, and to perform subgroup or 
adjusted analyses (if there is an imbalance in prognostic factors between 
the treatment arms).
Is used in clinical trial statistical analyses to evaluate or quantify a treatment-by-
factor interaction.
TABLE 2.  Differences between Prognostic and Predictive Factors
Prognostic Factor Predictive Factor
Is independent of treatment. Is dependent on a specific treatment.
The magnitude and direction of the treatment effect are the same 
across subsets of patients, but the response is consistently higher 
in one subset than another across the treatment arms (e.g., women 
have higher response than men on Tx A and Tx B).
The magnitude and/or the direction of the effect changes from one subset to another 
(e.g., smaller effect of Tx A compared with Tx B in women than in men).
Results are replicated across multiple studies of multiple different 
treatments within the same (or similar) disease state.
Results are replicated across several studies, containing the same experimental 
treatment (however, potentially having different control arms) within the same (or 
similar) disease state.
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of 20%, whereas those on Tx B had an RR of 50%, also a dif-
ference of 30%. Thus, both women and men had a treatment 
difference in response of 30%, but men had lower responses 
than women (20% versus 30% on Tx A and 50% versus 60% 
on Tx B). This lower response for men, compared with that for 
women, suggests that sex is prognostic.
Furthermore, when statistical modelling was used, the p 
value for the sex effect was 0.04, confirming the prognostic effect 
of sex. However, when a treatment-by-sex interaction test was per-
formed, the p value was 0.65, supporting that sex is not predictive.
Example 3—Sex: Not prognostic, but predictive  
(quantitative interaction)
In several hypothetical trials, there has not been any 
indication that women have a better or worse response than 
men, suggesting sex has no prognostic effect (Fig. 1C). In 
this hypothetical clinical trial, women had a 30% RR on Tx A 
compared with 60% for Tx B, a difference of 30%. In contrast, 
men had a 30% RR on Tx A versus 45% on Tx B, a difference 
of only 15%. In this example, the magnitude of the treatment 
effect (difference in RR) differs, suggesting a quantitative 
interaction.
Formal statistical evaluation using an interaction test 
between treatment and sex resulted in a p value of 0.025, 
supporting sex to be predictive but not prognostic because 
the RR on the control arm (Tx A) was the same for both 
sexes.
Example 4—Sex: Not prognostic but predictive  
(qualitative interaction)
In the same hypothetical example, women again had a 
30% improved RR on Tx B compared with Tx A (60% versus 
30%) (Fig. 1D). However in men, the RR was worse on Tx B 
than on Tx A by 20%. Hence the direction of the treatment 
effect changed between the sexes, suggesting a qualitative 
interaction. A statistical model evaluating these data showed 
evidence of a predictive effect, with an interaction p value 
of 0.001.
Example 5—Estrogen receptor status: Prognostic 
(positively) and predictive (positively)
In breast cancer, patients with estrogen receptor (ER) 
positive status, tend to live longer than those with ER nega-
tive status (Fig. 1E). In a hypothetical trial, patients with ER 
FLoWCHArT 1.  Prespecified analyses: Inferential regression models. 
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positive disease had a 5-year survival rate of 70%, whereas 
those with ER negative disease had a 5-year survival rate 
of 50%; statistical analysis confirmed the prognostic value 
of ER status with a p value of 0.02 (not shown in Fig. 1E). 
Similar results have been shown across other trials, with other 
treatments.
In addition, in this hypothetical trial, patients who were 
ER positive and received Tx B had a 5-year survival rate of 
80%, compared with 60% for those who received Tx A. In 
contrast, patients who were ER negative and received Tx B 
had a 5-year survival rate of 50% versus 40% for those who 
received Tx A. The interaction test of treatment and ER sta-
tus produced a p value of 0.01, also supporting the predictive 
value of ER status.
These hypothetical results show that ER positivity is both 
prognostic and predictive, because ER-positive patients had a 
better prognosis than those who are ER negative. In addition, 
ER-positive patients also had a larger treatment effect with Tx 
B than those treated with Tx A, compared with patients who 
are ER negative and were treated with either agent.
Example 6—HER2 receptor status: Prognostic 
(negatively) and predictive (positively)
This example (Fig. 1F) continues from example 5. The 
HER2 receptor status in breast cancer has been shown to be 
associated with poor prognosis. In various hypothetical trials, 
the illustrated results show that HER2 is both prognostic and 
predictive, because patients who are HER2 positive had a worse 
prognosis than those who are HER2 negative on the control arm, 
Tx A (i.e., negatively prognostic). In addition, patients who are 
HER2 positive also had a smaller treatment effect with Tx B than 
those treated with Tx A, compared with patients who are HER2 
negative (i.e., positively predictive; a quantitative interaction 
is shown, with a positive benefit for both HER2-negative and 
-positive patients—although, a larger magnitude for HER2-
negative, and a small magnitude for HER2-positive patients).
Results: When controlling for other 
baseline factors, gender effect is 
stascally significant
Conclusion: Gender is prognosc
Hypothesis:  Is gender both 
prognosc and predicve?
Acon: Expand mulvariate model 
to assess predicve role 
(interacon test of gender and 
treatment)
Results: When controlling for 
other baseline factors, gender 
effect not stascally significant
Conclusion: No evidence that 
gender is prognosc
Acon: STOP; report p-value for 
gender from univariate and 
mulvariate models
Note: this is a common approach to model building, other approaches may be used.  One 
approach may be to assess for predicve factors only, rather than both prognosc and 
predicve.
Hypothesis: Is a factor 
prognosc and/or 
predicve (e.g., gender)?
Acon: Build univariate 
model (only gender in the
model) 
Results: Gender effect not 
stascally significant
Conclusion:  No evidence that 
gender is prognosc
Acon: STOP; report p-value 
for gender from univariate
model 
Results: Gender effect stascally 
significant
Conclusion: Gender appears to be 
prognosc, at least on its own.
Hypothesis:  Is gender sll prognosc 
when other factors are considered?
Acon: Build mulvariate model with 
gender, treatment, and other factors
Results: Treatment-by-gender 
interacon not  stascally 
significant
Conclusion:  Gender is 
prognosc, but not predicve
Acon: STOP; report p-value for 
gender from univariate  and 
mulvariate models, and 
interacon test p-value
Results: Treatment-by-gender 
interacon stascally 
significant
Conclusion:  Gender is 
prognosc and predicve
Acon: STOP; report 
interacon test p-value and 
subgroup results
FLoWCHArT 2.  Model building to determine 
prognostic and predictive factors. 
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Example 7—Age (continuous): Prognostic but  
not predictive
This example (Fig. 1G) follows on from the previous 
examples. However, in this case, the factor of interest is con-
tinuous, as opposed to being binary.
In locally advanced cancers, increasing age has been 
shown to increase the risk of cancer recurrence. In the hypo-
thetical data shown here, for every 5-year increase in age 
(starting at the age of 40 years) for patients on Tx A, there was 
a 2% increase in the recurrence rate; hence, at 40 years of age, 
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FIGUrE 1.  Hypothetical examples 
of prognostic and predictive factors.
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the risk of recurrence was 20%, whereas at 70 years, it was 
32%. For patients receiving TxB, the risk of recurrence for a 
40-year old was 35%, whereas the risk of recurrence at age 70 
was 47%. The treatment difference in the risk of recurrence 
was 15%, at both 40 and 70 years of age. When statistical 
modeling was used, the p value for age was 0.025, confirm-
ing the prognostic effect of age. However, when a treatment-
by-age interaction test was performed, the p value was 0.45, 
indicating that age is not predictive.
SUMMArY
Identification of prognostic factors in a given disease 
setting is important. These prognostic factors enable appro-
priate planning of further clinical research and determine 
which type of patients would be appropriate for a given trial. 
Understanding of prognostic factors enables the clinician to 
evaluate other research and determine its applicability to his or 
her patients, through an assessment of how similar the patients 
included in that research are to those in the clinician’s practice.
Predictive factors are critically important in being able 
to tailor therapy to a given patient. If a patient has a certain 
profile, and it is known that a certain therapy works better for 
patients with that particular profile, then clinicians are able to 
ensure that the patients get the best therapy to prolong their 
survival and/or maintain quality of life.
Clinicians need clear descriptions and analyses from 
published literature to determine whether a factor is prog-
nostic or predictive. This can be achieved by giving the com-
plete regression analysis in a table, including all the factors 
and results (point estimates; 95% confidence intervals; and 
p values) from that regression model.6 Interaction tests need to 
be clearly described as such to ensure accuracy of interpreta-
tion (e.g., either by using the actual term interaction test or 
by adequately describing the variable—e.g., treatment-by-sex 
interaction).
One limitation of interactions tests is that they often 
have low statistical power, hence, a significant interaction 
p value may not be observed, even if the factor is truly pre-
dictive.7 Of note, studies are usually designed and powered 
for testing a treatment effect on the primary endpoint in the 
overall study population, not for subgroup analyses and/or 
an interaction test.7–9 Multiple significance testing can also 
make it seem that there is a subgroup effect, even when there 
is no real effect (i.e., observed by chance alone); appropriate 
testing using gatekeeping, and/or p value adjustment should 
be considered.1,7,10,11 Ideally, studies should be adequately 
designed and/or powered for subgroup analyses and/or tests 
of interaction.1
The strongest evidence in support of prognostic and 
predictive factors is replication and consistency of findings 
across several large trials, and/or in confirmatory studies, 
with the addition of biologic rationale to support the findings. 
Subgroup results (either prognostic or predictive) are gener-
ally considered hypothesis generating until they can be repro-
duced across several large studies (or in a meta-analysis), with 
an appropriate underlying biologic plausibility.1,2,7,9,10 Further 
evaluation of prognostic and predictive factors in clinical tri-
als is urgently needed to advance our understanding of dis-
eases and enable further tailoring of therapy to obtain the best 
patient outcomes.
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